Photopharmics kickstarts phototherapy trial for Parkinson’s disease

Equipment manufacturer Photopharmics has announced the initiation of its ‘Celeste light for PD’ clinical trial investigating the Celeste phototherapy device.

The US Food and Drug Administration (FDA)-approved device targets photoreceptors in the eye responsible for circadian signalling. Research has shown that Parkinson’s disease can damage the retina and impact the circadian system leading to symptoms such as trouble sleeping, cognition, depression, and fatigue.